Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and chief scientific officer Joseph Araujo joined Proactive's Stephen Gunnion to discuss three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds the company has identified.
While much of the industry focus has been on classic psychedelic drugs, Lanthier and Araujo told Proactive that Mindset has purposefully expanded its discovery efforts beyond the tryptamine drug class — psilocybin and N,N-Dimethyltryptamine (DMT) — into new, innovative chemical structures in order to develop superior neuropsychiatric medications.